Beam Therapeutics (BEAM) Income from Continuing Operations (2019 - 2026)
Beam Therapeutics' (BEAM) quarterly Income from Continuing Operations came in at 98308000.0 in Q1 2026, up 10.25% year-on-year from 89167177.81 in Q1 2025, and down 137.65% on a QoQ basis from 261096000.0 in Q4 2025.
Beam Therapeutics (BEAM) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has 8 years of Income from Continuing Operations data on file, last reported at 98308000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 10.25% year-over-year to 98308000.0 in Q1 2026; TTM through Mar 2026 was 52231000.0, a 86.52% increase from a year earlier, with the FY2025 full-year figure at 63193000.0, up 83.23% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 98308000.0, down from 261096000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for BEAM reached as high as 261096000.0 in Q4 2025 and fell as low as 176199000.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 61886529.41 across 5 years, with a median of 92710000.0 in 2024.
- Across the five-year window, Income from Continuing Operations plunged 199.01% in 2022 and jumped 472.27% in 2023, its largest moves.
- Year by year, Income from Continuing Operations stood at 38349000.0 in 2022, then soared by 472.27% to 142763000.0 in 2023, then sank by 163.29% to 90354000.0 in 2024, then surged by 388.97% to 261096000.0 in 2025, then plunged by 137.65% to 98308000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 98308000.0 in Q1 2026, 261096000.0 in Q4 2025, and 112728000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Beam Therapeutics | 2.68 Bn | 2.68 Bn | - | -98.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -98.31 Mn |
| Dec 31, 2025 | 261.10 Mn |
| Sep 30, 2025 | -112.73 Mn |
| Jun 30, 2025 | -102.29 Mn |
| Mar 31, 2025 | -109.54 Mn |
| Dec 31, 2024 | -90.35 Mn |
| Sep 30, 2024 | -96.67 Mn |
| Jun 30, 2024 | -91.05 Mn |
| Mar 31, 2024 | -92.71 Mn |
| Dec 31, 2023 | 142.76 Mn |
| Sep 30, 2023 | -96.09 Mn |
| Jun 30, 2023 | -82.78 Mn |
| Mar 31, 2023 | -89.15 Mn |
| Dec 31, 2022 | -38.35 Mn |
| Sep 30, 2022 | -84.08 Mn |
| Jun 30, 2022 | -176.20 Mn |
| Mar 31, 2022 | -95.65 Mn |
| Dec 31, 2021 | -64.71 Mn |
| Sep 30, 2021 | -28.12 Mn |
| Jun 30, 2021 | -61.34 Mn |